Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: A prospective, multi-center, double-blind, randomized phase II trial

Shock

Volumn 5, Issue 5, 1996, Pages 313-319

  Froon, Albert M F ^a   Greve, Jan Willem M ^a   Buurman, Wim A ^a   Van Der Linden, Cees J ^b   Langemeijer, Han J M ^c   Ulrich, Chris ^d   Bourgeois, Marc ^e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

^e General Hospital St Jan   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; ANTITHROMBOCYTIC AGENT; ISOQUINOLINE DERIVATIVE; PYRIDINIUM DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PYRIDINIUM COMPOUNDS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 0030133079     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199605000-00001     Document Type: Article

References (36)

1. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA: Sepsis syndrome: A valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 17:389-393, 1989.
2. Bone RC: A critical evaluation of new agents for the treatment of sepsis. J Am Med Assoc 266:1686-1691, 1991.
3. Wenzel RP, Andriole VT, Bartlett JG, et al: Antiendotoxin monoclonal antibodies for Gram-negative sepsis: Guidelines from the IDSA. Clin Infect Dis 14:973-976, 1992.
4. Molloy RG, Mannick JA, Rodrick ML: Cytokines, sepsis and immunomodulation. Br J Surg 80:289-297, 1993.
5. Giroir BP: Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 21:780-789, 1993.
6. Dofferhoff AS, Bom VJ, de Vries Hospers HG, et al: Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 20:185-192, 1992.
7. Hack CE, Hart M, van Schijndel RJ, et al: Interleukin-8 in sepsis: Relation to shock and inflammatory mediators. Infect Immun 60:2835-2842, 1992.
8. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552, 1990.
9. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429-436, 1991.
10. Exley AR, Cohen J, Buurman W, et al: Monoclonal antibody to TNF in severe septic shock. Lancet 335:1275-1277, 1990.
11. Moller A, Emling F, Blohm D, Schlick E, Schollmeier K: Monoclonal antibodies to human tumor necrosis factor alpha: In vitro and in vivo application. Cytokine 2:162-169, 1990.
12. Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. J Am Med Assoc 271:1836-1843, 1994.
13. Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 21:318-327, 1993.
14. LoBuglio AF, Wheeler RH, Trang J, et al: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 86:4220-4224, 1989.
15. Ou MC, Kambayashi J, Kawasaki T, et al: Potential etiologic role of PAF in two major septic complications: Disseminated intravascular coagulation and multiple organ failure. Thromb Res 73:227-238, 1994.
16. Qian C, Guo ZM, Peters CJ, Liu CT: Platelet-activating factor (PAF)-induced cardiopulmonary dysfunctions and their reversal with a PAF antagonist (BN 52021) in strain 13 guinea pigs. J Lipid Medial 7:223-237, 1993.
17. Braquet P, Touqui L, Shen TY, Vargaftig BB: Perspectives in platelet-activating factor research. Pharmacol Rev 39:97-145, 1987.
18. Anderson BO, Bensard DD, Harken AH: The role of platelet-activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet 172:415-424, 1991.
19. Kuipers B, van der Poll T, Levi M, et al: Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. J Immunol 152:2438-2446, 1994.
20. Chang SW, Fernyak S, Voelkel NF: Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury. Am J Physiol 258:H153-H158, 1990.
21. Yue TL, Farhat M, Rabinovici R, Perera PY, Vogel SN, Feuerstein G: Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits. J Pharmacol Exp Ther 254:976-981, 1990.
22. Yamanaka S, Iwao H, Yukimura T, Kim S, Miura K: Effect of the platelet-activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock. Br J Pharmacol 110:1501-1507, 1993.
23. Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K: Beneficial effects of TCV-309, a novel potent and selective platelet-activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther 260:748-755, 1992.
24. Kawamura M, Terashita Z, Imura Y, Shino A, Nishikawa K: Inhibitory effect of TCV-309, a novel platelet-activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: Possible role of PAF in tissue factor generation. Thromb Res 70:281-293, 1993.
25. Ogata M, Matsumoto T, Koga K, et al: An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect Immun 61:699-704, 1993.
26. Goris RJA, Boekhorst TPA, Nuytinck JKS, Gimbrere JSF: Multiple-organ failure: Generalized autodestructive inflammation? Arch Surg 120:1109-1115, 1985.
27. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356-362, 1992.
28. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 103:565-575, 1993.
29. Calandra T, Baumgartner JD, Grau GE, et al: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis 161:982-987, 1990.
30. Bone RC; American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
31. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: Apache II: A severity of disease classification for severely ill patients. Crit Care Med 13:818-829, 1985.
32. Engelberts I, Moller A, Schoen GJ, van der Linden CJ, Buurman WA: Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 10:69-76, 1991.
33. Dentener MA, Bazil V, von Asmuth EJ, Ceska M, Buurman WA: Involvement of CD 14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 150:2885-2891, 1993.
34. Leeuwenberg JF, Smeets EF, Neefjes JJ, et al: E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543-549, 1992.
35. Newman W, Beall LD, Carson CW, et al: Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 150:644-654, 1993.
36. Makristathis A, Stauffer F, Feistauer SM, Georgopoulos A: Bacteria induce release of platelet-activating factor (PAF) from polymorphonuclear neutrophil granulocytes: Possible role for PAF in pathogenesis of experimentally induced bacterial pneumonia. Infect Immun 61:1996-2002, 1993.